 GREENFIELD, Ind.--BUSINESS WIRE--Elanco Animal Health Incorporated NYSE: ELAN today announced an agreement with Kindred Biosciences NASDAQ: KIN to acquire exclusive global rights to KIND-030, a first-of-its-kind monoclonal antibody being developed for the treatment and prevention of canine parvovirus CPV. This deadly disease impacts at least 250,000 puppies annually in the U.S., according to Banfield Pet Hospital1, with no approved treatment available. Data from BluePearl Specialty and 